Market research
ITCI Intracellular Th
Current ticker: ITCI
NASDAQ USD Healthcare
Latest close
As of 30 Apr 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 132
- Dividend yield
- Not available
- Beta
- 0.46
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 132
- Dividend yield
- Not available
- Beta
- 0.46
About
About Intracellular Th
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Research context
Intracellular Th appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ITCI discussion.
5 years, 7 months ago
Intra-Cellular Therapies, Inc is currently in a long term uptrend where the price is trading 28.4% above its 200 day moving average.
From a valuation standpoint, the stock is 92.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 101.4.
Intra-Cellular Therapies, Inc's total revenue rose by 20447.2% to $12M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-61K since the same quarter in the previous year.
Finally, its free cash flow fell by 91.3% to $-68M since the same quarter in the previous year.
Based on the above factors, Intra-Cellular Therapies, Inc gets an overall score of 4/5.